248 related articles for article (PubMed ID: 26307357)
1. Fifty seven years of follow-up of the Israeli cohort of Laron Syndrome patients-From discovery to treatment.
Laron Z; Kauli R
Growth Horm IGF Res; 2016 Jun; 28():53-6. PubMed ID: 26307357
[TBL] [Abstract][Full Text] [Related]
2. A half-century of studies of growth hormone insensitivity/Laron syndrome: A historical perspective.
Rosenbloom AL
Growth Horm IGF Res; 2016 Jun; 28():46-50. PubMed ID: 26276451
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
Laron Z
Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
[TBL] [Abstract][Full Text] [Related]
4. IGF-I deficiency, longevity and cancer protection of patients with Laron syndrome.
Laron Z; Kauli R; Lapkina L; Werner H
Mutat Res Rev Mutat Res; 2017; 772():123-133. PubMed ID: 28528685
[TBL] [Abstract][Full Text] [Related]
5. Laron syndrome - A historical perspective.
Laron Z; Werner H
Rev Endocr Metab Disord; 2021 Mar; 22(1):31-41. PubMed ID: 32964395
[TBL] [Abstract][Full Text] [Related]
6. Primary growth hormone (GH) insensitivity and insulin-like growth factor deficiency caused by novel compound heterozygous mutations of the GH receptor gene: genetic and functional studies of simple and compound heterozygous states.
Fang P; Riedl S; Amselem S; Pratt KL; Little BM; Haeusler G; Hwa V; Frisch H; Rosenfeld RG
J Clin Endocrinol Metab; 2007 Jun; 92(6):2223-31. PubMed ID: 17405847
[TBL] [Abstract][Full Text] [Related]
7. LESSONS FROM 50 YEARS OF STUDY OF LARON SYNDROME.
Laron Z
Endocr Pract; 2015 Dec; 21(12):1395-402. PubMed ID: 26401581
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone insensitivity syndrome caused by a heterozygous GHR mutation: phenotypic variability owing to moderation by nonsense-mediated decay.
Gorbenko del Blanco D; de Graaff LC; Visser TJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2012 May; 76(5):706-12. PubMed ID: 22117696
[TBL] [Abstract][Full Text] [Related]
9. Long-term IGF-I treatment of children with Laron syndrome increases adiposity.
Laron Z; Ginsberg S; Lilos P; Arbiv M; Vaisman N
Growth Horm IGF Res; 2006 Feb; 16(1):61-4. PubMed ID: 16442822
[TBL] [Abstract][Full Text] [Related]
10. Biphasic response of subscapular skinfold thickness to hGH or IGF-1 administration to patients with congenital IGHD, congenital MPHD and Laron syndrome.
Bisker-Kassif O; Kauli R; Lilos P; Laron Z
Obes Res Clin Pract; 2014; 8(1):e55-62. PubMed ID: 24548577
[TBL] [Abstract][Full Text] [Related]
11. Novel growth hormone receptor gene mutation in a patient with Laron syndrome.
Arman A; Yüksel B; Coker A; Sarioz O; Temiz F; Topaloglu AK
J Pediatr Endocrinol Metab; 2010 Apr; 23(4):407-14. PubMed ID: 20583548
[TBL] [Abstract][Full Text] [Related]
12. Primary GH insensitivity '(Laron syndrome) caused by a novel 4 kb deletion encompassing exon 5 of the GH receptor gene: effect of intermittent long-term treatment with recombinant human IGF-I.
Besson A; Salemi S; Eblé A; Joncourt F; Gallati S; Jorge AA; Mullis PE
Eur J Endocrinol; 2004 May; 150(5):635-42. PubMed ID: 15132718
[TBL] [Abstract][Full Text] [Related]
13. A novel GHR intronic variant, c.266+83G>T , activates a cryptic 5' splice site causing severe GHR deficiency and classical GH insensitivity syndrome.
Feigerlova E; Swinyard M; Derr MA; Farnsworth J; Andrew SF; Rosenfeld RG; Hwa V
Horm Res Paediatr; 2013; 80(6):397-405. PubMed ID: 24296660
[TBL] [Abstract][Full Text] [Related]
14. Clinical, Endocrine, and Molecular Genetic Analysis of a Large Cohort of Saudi Arabian Patients with Laron Syndrome.
Al-Ashwal AA; Al-Sagheir A; Ramzan K; Al-Owain M; Allam R; Qari A; Al-Numair NS; Imtiaz F
Horm Res Paediatr; 2017; 88(2):119-126. PubMed ID: 28743110
[TBL] [Abstract][Full Text] [Related]
15. Novel splice site mutation in the growth hormone receptor gene in Turkish patients with Laron-type dwarfism.
Arman A; Ozon A; Isguven PS; Coker A; Peker I; Yordam N
J Pediatr Endocrinol Metab; 2008 Jan; 21(1):47-58. PubMed ID: 18404972
[TBL] [Abstract][Full Text] [Related]
16. Effects of heterozygosity for the E180 splice mutation causing growth hormone receptor deficiency in Ecuador on IGF-I, IGFBP-3, and stature.
Guevara-Aguirre J; Rosenbloom AL; Guevara-Aguirre M; Yariz K; Saavedra J; Baumbach L; Shuster J
Growth Horm IGF Res; 2007 Jun; 17(3):261-4. PubMed ID: 17350302
[TBL] [Abstract][Full Text] [Related]
17. Changes in plasma amino acids metabolites, caused by long-term IGF-I deficiency, are reversed by IGF-I treatment - A pilot study.
Barazani C; Werner H; Laron Z
Growth Horm IGF Res; 2020 Jun; 52():101312. PubMed ID: 32200226
[TBL] [Abstract][Full Text] [Related]
18. Laron syndrome: clinical features, molecular pathology and treatment.
Laron Z; Klinger B
Horm Res; 1994; 42(4-5):198-202. PubMed ID: 7868073
[TBL] [Abstract][Full Text] [Related]
19. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003.
Laron Z
J Clin Endocrinol Metab; 2004 Mar; 89(3):1031-44. PubMed ID: 15001582
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Molecular Features of Laron Syndrome, A Genetic Disorder Protecting from Cancer.
Janecka A; Kołodziej-Rzepa M; Biesaga B
In Vivo; 2016; 30(4):375-81. PubMed ID: 27381597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
